TY -的T1神经异常症状和生活质量与急性non-hospitalized神经科门诊病人后遗症的COVID-19 (p8 - 9.005) JF -神经学首页乔-神经学做- 10.1212 / WNL。0000000000204322六世- 100 - 17补充2 SP - 4943 AU - Samarah Ahmed AU -萨拉·海曼盟瑞秋肯尼AU -雪莉Fung盟-阿齐兹Seixas盟Girardin jean - louis AU -史蒂文Galetta AU -劳拉Balcer AU -苏Thawani Y1 - 2023/04/25 UR - //www.ez-admanager.com/content/100/17_Supplement_2/4943.abstract N2 -目的:本研究的目的首页是评估神经异常症状和生活质量在PASC是从一个神经学门诊患者。背景:神经异常症状往往与COVID-19报道。复合自主症状量表31 (COMPASS-31)问卷是一个简单的和验证工具来评估dysautonomic症状。设计/方法:在后续的研究中一个基线群SARS-CoV-2 laboratory-positive病人评估之间的PASC 11月,2020年8月,2021年,49.5%(46/93)参与者完成随访电话问卷调查生活质量,神经和自主神经症状。结果:在1年随访问卷完成的46名参与者(63%的女性,平均年龄51±17年),其中95%的人接种COVID-19。其中,42个参与者完成了COMPASS-31规模。一个COMPASS-31 raw-score> 17表明自主功能障碍被发现在69%的受试者。COMPASS-31得分中位数为26.6 (SD = 17.1, = 0.89 - -56.9)范围。更COMPASS-31得分在1年随访Neuro-QoL-Anxiety t指数(p = 0.031,线性回归调整年龄,性别,种族/民族,和Neuro-QoL-Fatigue t指数(p = 0.003),但不是Neuro-QoL-Depression (p = 0.117)基线Neuro-QoL-Depression t指数与更多有关COMPASS-31分数在随访(p = 0.017),而Neuro-QoL-Anxiety (p = 0.152)和Neuro-QoL-Fatigue (p = 0.083)。报道持续的头晕/眩晕患者大COMPASS-31分数在1年随访(术中;0.0001调整年龄、性别、种族/民族)。这些报告头晕/眩晕在随访也意味着COMPASS-31原始分数20.6分高于不报告这个症状。头晕症状基线研究访问1年随访COMPASS-31分数不相关(p = 0.694)结论:这项研究支持自主症状监测的重要性作为可能的并发症可能会持续纵向的PASC神经学宗人群。首页 The greater COMPASS-31 raw scores may be informed by persistence of lightheadedness.Disclosure: Ms. Ahmed has nothing to disclose. Ms. Hyman has nothing to disclose. Rachel Kenney has nothing to disclose. Ms. Fung has nothing to disclose. Azizi Seixas has nothing to disclose. Girardin Jean-Louis has nothing to disclose. Dr. Galetta has nothing to disclose. An immediate family member of Dr. Balcer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Children’s Hospital of Philadelphia. Dr. Balcer has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for North American Neuro-Ophthalmology Society. Dr. Thawani has nothing to disclose. ER -